KRAS and colorectal cancer: However, evidence of acquired or de novo resistance to covalent G12C inhibitors has already been demonstrated, with only approximately 40% of patients showing partial response to KRAS-targeting monotherapies in lung adenocarcinoma and less than 20% in colorectal cancer [14].